Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Xtant Medical Holdings, Inc.AMEX: XTNT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $534K fell 50.3% year over year, behind the +9.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 70.6% from the prior quarter. Over 3 fiscal years it compounded at +59.3% a year.
Context
- Depreciation & amortization amounted to 3.9% of revenue in FY2025, up 0.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -50.3% toward the trailing-twelve-month pace of +9.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.22M USD
- Year-over-year change
- +23.7%
- 4-year CAGR
- +40.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.22M | +23.7% |
| FY2024 | 2024-12-31 | 4.22M | +33.1% |
| FY2023 | 2023-12-31 | 3.17M | +145.7% |
| FY2022 | 2022-12-31 | 1.29M | -3.0% |
| FY2021 | 2021-12-31 | 1.33M | — |
Depreciation & Amortization vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 depreciation & amortization of $4.68M is the 2nd largest of the 8 companies compared; the peer median is $2.15M.
- Its year-over-year change of +9.1% is the 5th highest of 8, against a peer median of +12.2%.
- Depreciation & amortization amounts to 3.8% of revenue for XTNT, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $429.44M | +48315.3% | -23.3% | 8364.7% | |
| LTM Mar 2026 | $4.68M | +9.1% | +59.3% | 3.8% | |
| LTM Mar 2026 | $4.61M | -17.9% | -18.0% | 4.4% | |
| LTM Mar 2026 | $3.11M | -8.6% | +4.7% | 9.0% | |
| LTM Mar 2026 | $2.15M | +48.5% | +53.1% | 3.0% | |
| LTM Mar 2026 | $719K | +24.0% | -9.7% | 1.3% | |
| LTM Mar 2026 | $452K | +12.2% | +3.6% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $219.19K | -179.7% | — | — |
| Peer median (excluding XTNT) | $2.15M | +12.2% | -3.0% | 4.4% | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Depreciation & Amortization | 1.33M | 1.29M | 3.17M | 4.22M | 5.22M |
| Deferred Income Tax | 0 | 0 | (1.9M) | 21K | 0 |
| Stock-Based Compensation | 2.21M | 2.46M | 2.74M | 4.12M | 2.89M |
| Change in Working Capital | 793K | (2.81M) | (3.63M) | (5.35M) | (3.05M) |
| Accounts Receivables | (319K) | (3.94M) | (8.74M) | (755K) | (591K) |
| Inventory | 2.62M | (1.15M) | (1.89M) | (2.49M) | (2M) |
| Accounts Payables | (332K) | 875K | 2.98M | 1.03M | (3.12M) |
| Other Working Capital | (1.18M) | 1.41M | 4.01M | (3.13M) | 2.66M |
| Other Non-Cash Items | 954K | 2.2M | (10.55M) | 1.54M | 2.5M |
| Operating Cash Flow | 439K | (5.34M) | (9.52M) | (11.9M) | 12.55M |
| Capital Expenditures | (2.12M) | (1.76M) | (1.46M) | (4.11M) | (2.38M) |
| Acquisitions (Net) | 0 | 0 | (23.5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 225K | 205K | 175K | 383K | 10.28M |
| Investing Cash Flow | (1.89M) | (1.56M) | (24.78M) | (3.73M) | 7.9M |
| Debt Repayment | (592K) | (291K) | 6.18M | 12.43M | (9.33M) |
| Common Stock Issued | 18.43M | 9.31M | 14.01M | 4.46M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (65K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (337K) | 9.07M | (500K) | (816K) | (175K) |
| Financing Cash Flow | 17.5M | 9.02M | 19.69M | 16.07M | (9.57M) |
| Effect of Forex Changes | 0 | 0 | 24K | (149K) | 232K |
| Net Change in Cash | 16.05M | 2.12M | (14.58M) | 298K | 11.11M |
| Free Cash Flow | (1.68M) | (7.11M) | (10.97M) | (16.01M) | 10.16M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.